

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Jean Pierre PLOUET et al.

Conf.

Application No. NEW NATIONAL PHASE

Group

Filed April 11, 2005

Examiner

NOVEL ENDOTHELIAL CELLS, ANTIBODIES DIRECTED AGAINST SAID CELLS AND
USE THEREOF, IN PARTICULAR FOR SCREENING ANGIOGENESIS INHIBITING
SUBSTANCES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 11, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of
the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby
submit(s) an Information Disclosure Statement for consideration by
the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for
consideration by the Office are listed on PTO-1449, attached
hereto.

II. COPIES

- ☒ Copies of the U.S. patents or publications are not submitted
since the USPTO has waived their submission for applications
filed after June 30, 2003.
- ☒ Submitted herewith is a legible copy of (i) each foreign
patent; (ii) each publication or that portion which caused it
to be listed; and (iii) all other information or that portion
which caused it to be listed.
- ☐ This application is a National Phase of a PCT application.
Some or all of the documents listed on the PTO-1449 are not
enclosed because they were cited in the International Search
Report and copies should have been forwarded from the
International Search Authority pursuant to the trilateral
agreement between the USPTO, EPO and JPO, or they are U.S.
patents or U.S. published applications. If copies are needed,
please contact the undersigned.

PTC 11 APR 2005

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An foreign language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEEs

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel

Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/yr

Enclosures: ☒ Form PTO-1449(s)
☒ Documents
☒ Foreign Search Report
☐ Other: _____

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Attorney Docket No.:
0508-1134

Application No.:
NEW NATIONAL PHASE

Applicant:
Jean Pierre PLOUET et al.

Filing Date:
April 11, 2005

Group Art Unit:

U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing date (if appropriate) |
|------------------|-----------------|-----------|---------------|-------|----------|------------------------------|
| | 5,976,782 | 11/2/1999 | PARISH et al. | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation | |
|------------------|-----------------|-----------|---------|-------|----------|-------------|----|
| | | | | | | Yes | No |
| | 2 796 073 | 1/12/2001 | FRANCE | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|---|
| | HARTLAPP I ET AL: "Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES OCT 2001, vol. 15, no. 12, octobre 2001 (2001-10), pages 2215-2224, XP002249066 ISSN: 1530-6860, *le document en entier* |
| | HUTCHINGS HELEN ET AL: "Pigment epithelium-derived factor exerts opposite effects on endothelial cells of different phenotypes.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 294, no. 4, 21 juin 2002 (2002-06-21), pages 764-769, XP002249067, June 21, 2002, ISSN: 0006-291X, *le document en entier* |
| | MEADOWS K N ET AL: "Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 28 DEC 2001, vol. 276, no. 52, 28 decembre 2001 (2001-12-28), pages 49289-49298, XP002249068, ISSN: 0021-9258, *le document en entier* |
| | WITTE LARRY et al., "MONOCLONAL ANTIBODIES TARGETING THE VEGF RECEPTOR-2 (FLK1/KDR) AS AN ANTI-ANGIOGENIC THERAPEUTIC STRATEGY", 155-161, 1998 |
| | |
| | |
| | |
| | |

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience